FDA Grants Full Approval to Rucaparib for BRCA Mutation–Associated mCRPC
Posted OnDecember 19, 2025 byThe FDA has granted regular approval to rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer.Read More…
FDA Approves Niraparib and Abiraterone Acetate with Prednisone for mCSPC
Posted OnDecember 17, 2025 byOn December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).Read More…
Open Clinical Trials for BRCA Carriers
Posted OnOctober 29, 2025 byResearch helps scientists and doctors better understand health and disease, leading to new ways to prevent, diagnose, and treat illnesses. By participating in a clinical trial, you can play a vital role in advancing discoveries that may improve health outcomes for everyone.Read More…
Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening
Posted OnOctober 16, 2025 byScientists at The Institute of Cancer Research, London, are calling for targeted screening after finding that PSA testing picked up more dangerous prostate cancers in men with BRCA1 and BRCA2 mutations than non-carriers.Read More…
The Gray Pre-Cancer Atlas
Posted OnOctober 1, 2025 byMen and women with mutations in either the BRCA1 or BRCA2 gene are at an increased risk of developing certain cancers, including breast, ovarian, pancreatic, or prostate.Read More…
CureBRCA Grant Recipients
Posted OnOctober 1, 2025 byFunded research includes grants to U.S. and international academic institutions: projects include research, screening, treatment, and outreach efforts for men with BRCA genetic mutations.Read More…
Elevated Cancer Risk in BRCA+ Men
Posted OnJuly 21, 2025 byDrs. Kara Maxwell, Daniel Lee, Jennifer Zhang and Bryson Katona review the nuances of BRCA+ breast, prostate, and pancreatic cancers in men.Read More…
CureBRCA Partners with Ann & Robert H. Lurie Children’s Hospital of Chicago
Posted OnJanuary 9, 2025 byCureBRCA is partnering with the Ann & Robert H. Lurie Children’s Hospital of Chicago in support of the Polsky Family Genetic Testing Initiative. This collaboration will expand access to vital genetic testing for patients and families, with an estimated 275 individuals benefiting through the Cancer Predisposition Program in Lurie Children’s Center for Cancer and Blood Disorders.Read More…
2025 Research Program
Posted OnJanuary 3, 2025 byCureBRCA will consider funding BRCA-related initiatives that involve prevention, detection, screening, and/or treatment for men at risk for BRCA-related cancers. Applications are due by March 15, 2025.Read More…
